ICML 2019 | How could azacitidine with romidepsin be integrated into the treatment pathway of T-cell lymphomas?

L:

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Lorenzo Falchi from Columbia University Medical Center, New York, US, about how oral azacitidine and romidepsin could fit into the management of patients with T-cell lymphomas.

Lorenzo Falchi discusses that this combination has been shown to be much more active in t-cell lymphoma than in other lymphomas, which was the drive towards the phase II trial investigating the same combination. Early results of trial showed promising results, with the main adverse events being infections and cytopenias.